Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
Phase 2 N=237 Efficacy of Varenicline for Smokeless Tobacco Use in India
Tobacco Use Disorder
Primary: 7-day Point Prevalence Smokeless Tobacco Abstinence Biochemically Confirmed With Urine Cotinine at the End of 12 Weeks of Treatment. — 30; 23 participants
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=359 Novel Determinants and Measures of Smokeless Tobacco Use: Study 1
Smokeless Tobacco Use · Tobacco Dependence
Primary: Extent of Toxicity: Mean of Median Values of NNK+NNN in 7 Smokeless Tobacco Brands — 2.4; 2.25; 3.19; 5.51 ug/g
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
N/A N=231 A Study to Evaluate Changes in Smokers Using Oral Tobacco-derived Nicotine Products.
Tobacco Use
Primary: Summary of Urine Total NNAL Amount Excreted and Absolute Change From Baseline (ng/24 Hour) by Study Group and Study Day (mITT Population) — 511.889; 581.676; 548.751…
N/A N=85 Assessing Toxicity of Waterpipe Tobacco Smoking
Waterpipe Smoking
Primary: Comparing Cotinine Pre-to-post Change Between 2 Waterpipe Smoking Sessions: Heating Waterpipe Tobacco by (a) Charcoal vs (b) an Electric Head — 34.9; 26.4 ng/mL — p=0.115
N/A N=1,257 Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
Phase 4 N=181 Cannabis and Tobacco Co-use Study
Tobacco Use Disorder
Primary: Number of Participants With Biologically Verified 7-day Point Prevalence Tobacco Abstinence at the End of Treatment (Week 12) — 30; 40; 36; 42 Participants
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 2 N=332 Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use
Tobacco Use Disorder
Primary: Percent Abstinent From Tobacco at Week 12 (7 Day Point Prevalence) — 31; 17 percentage of randomized — p=0.04
N/A N=64 Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)
Tobacco Use
Primary: Number of Cigarettes Purchased — 154.7; 119.2 average number of cigarettes
N/A N=60 Smoking Topography and Harm Exposure in Menthol Cigarettes
Cigarette Smoking Toxicity
Primary: Smoking Topography- Puff Volume — 518; 661; 650; 620 mL
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
N/A N=67 Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
N/A N=30 Quit or Switch: E-cigarette Study
Tobacco Use
Primary: Percentage of Participants Who Report Daily Use of E-cigarettes or NRT and no Cigarette Use
N/A N=76 Varenicline for the Treatment of Smokeless Tobacco
Nicotine Dependence
Primary: 7-day Point Prevalence All Tobacco Abstinence — 21; 16 participants — p=0.126
Phase 4 N=432 Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
Tobacco Use Cessation
Primary: Number of Subjects With a 4 Week Continuous Quit Rate (CQR) From Smokeless Tobacco — 125; 85 participants — p=<0.0001
Phase 2 N=38 Treating Smokers With Mental Illness
Smoking Cessation · Cigarette Smoking · Schizophrenia
Primary: 7-Day Point Prevalence Abstinence — 5; 3; 4; 5 Participants